Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Avadel Pharmaceuticals plc is a drug manufacturers-specialty & generic business based in the US. Avadel Pharmaceuticals shares (AVDL) are listed on the NASDAQ and all prices are listed in US Dollars. Avadel Pharmaceuticals employs 50 staff and has a trailing 12-month revenue of around USD$33.3 million.
|Latest market close||USD$6.82|
|52-week range||USD$4 - USD$12|
|50-day moving average||USD$6.8932|
|200-day moving average||USD$6.9692|
|Wall St. target price||USD$17.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.324|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-0.58%|
|1 month (2020-12-16)||-6.32%|
|3 months (2020-10-16)||24.91%|
|6 months (2020-07-16)||-15.80%|
|1 year (2020-01-16)||-11.08%|
|2 years (2019-01-16)||165.37%|
|3 years (2018-01-16)||10.61|
|5 years (2016-01-15)||10.04|
Valuing Avadel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avadel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Avadel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Avadel Pharmaceuticals shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Avadel Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.07. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Avadel Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$33.3 million|
|Gross profit TTM||USD$47.1 million|
|Return on assets TTM||-7.61%|
|Return on equity TTM||21.59%|
|Market capitalisation||USD$402.1 million|
TTM: trailing 12 months
There are currently 4.1 million Avadel Pharmaceuticals shares held short by investors – that's known as Avadel Pharmaceuticals's "short interest". This figure is 6.5% down from 4.4 million last month.
There are a few different ways that this level of interest in shorting Avadel Pharmaceuticals shares can be evaluated.
Avadel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Avadel Pharmaceuticals shares currently shorted divided by the average quantity of Avadel Pharmaceuticals shares traded daily (recently around 483229.52941176). Avadel Pharmaceuticals's SIR currently stands at 8.5. In other words for every 100,000 Avadel Pharmaceuticals shares traded daily on the market, roughly 8500 shares are currently held short.
However Avadel Pharmaceuticals's short interest can also be evaluated against the total number of Avadel Pharmaceuticals shares, or, against the total number of tradable Avadel Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avadel Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Avadel Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Avadel Pharmaceuticals shares, roughly 0 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Avadel Pharmaceuticals.
Find out more about how you can short Avadel Pharmaceuticals stock.
We're not expecting Avadel Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Avadel Pharmaceuticals's shares have ranged in value from as little as $4 up to $12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avadel Pharmaceuticals's is 1.6063. This would suggest that Avadel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.